Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > New Chemical Entities, Drug Leads

Categories

[Search within category]

Antibody Selection to Prevent or Treat Alzheimer’s Disease

Therapeutic antibodies have been developed to prevent or slow the cognitive decline in Alzheimer’s disease (AD) but with limited clinical success to date. These treatment failures suggest that antibodies vary in their therapeutic efficacy and that more effective antibodies or combinations of antibodies need to be identified. To address this issue, researchers at UCI have developed a novel screening platform that can identify antibodies that may prevent or treat AD or other neurodegenerative disorders with high efficacy from human blood.

Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain

Researchers at the University of California, Davis, have developed a dual soluble epoxide hydrolase (sEH)/ phosphodiesterase 4 (PDE4) inhibitor for the treatment of inflammatory pain.

Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders

Researchers at the University of California, Davis have developed small molecule inhibitors to prevent or reverse the progression of neurodegenerative diseases or symptoms.

PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity

Researchers at the University of California, Davis have discovered a compound that inhibits both cyclooxygenase-2 (COX-2) /soluble epoxide hydrolase (sEH) to improve effectiveness of chemotherapy while protecting normal tissue from cisplatin toxicity.

Joint Pharmacophoric Space through Geometric Features

Pharmacophore analysis through examination of Joint Pharmacophore Space of chemical compounds, targets, and chemical/biological properties.

Selective Voltage Gated KV1.3 Potassium Channel Inhibitors

Researchers at the University of California, Davis, have discovered a composition of 5-phenoxyalkoxypsoralens that inhibits potassium channels to treat autoimmune diseases and disorders that involve abnormal homeostasis, body weight and peripheral insulin sensitivity.

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

Novel Therapy for Treating Fungal Infection of the Cornea

Fungal keratitis is an infection of the cornea caused by pathogenic fungi that is challenging to treat. This therapy is a novel topical application of a commercially-available malarial drug to treat fungal keratitis with fewer side effects than current treatments.

Inhibition of Pyruvate Oxidation to Promote Hair Growth

UCLA researchers in the departments of Molecular, Cell & Developmental Biology and Biological Chemistry have elucidated a novel mechanism by which pyruvate oxidation can be inhibited in order to promote hair growth.

Genes, Proteins and Small Molecule Networks Responsible for Neuronal Regeneration

Through integrative analyses of the regeneration-associated gene expression profiling after peripheral nervous system (PNS) injury, combined with multi-level bioinformatics and experimental validation of network predictions, UCLA researchers in the Department of Neurology have identified a small molecule drug that significantly accelerates and improves dorsal root ganglia (DRG) neurite outgrowth in vitro and optic nerve outgrowth in vivo.

Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy

Researchers at the University of California, Davis, have adapted novel soluble epoxide hydrolase (sEHI) inhibitors as adjuvant treatment in cardiac cell-based therapy to improve the survival and engraftment of stem cells by pre-conditioning with the sEHI in vitro.

Inhibitors Of Zika Virus

UCLA researchers in the Department of Psychiatry and Biobehavioral Sciences, Department of Radiation Oncology and Department of Pathology have identified sulfonamide-based small molecules that show anti-Zika activity at low nanomolar range.

Novel Inhibitor of HIV Replication

UCLA researchers in the David Geffen School of Medicine have discovered a new small molecule inhibitor for HIV-1 replication.

A Highly Error-Prone Orthogonal Replication System For Targeted Continuous Evolution In Vivo

Inventors at UC Irvine have engineered an orthogonal DNA replication system capable of rapid, accelerated continuous evolution. This system enables the directed evolution of specific biomolecules towards user-defined functions and is applicable to problems of protein, enzyme, and metabolic pathway engineering.

Small Molecule Regulators of let-7 MicroRNA Targets in Acute Myeloid Leukemia Cancer Stem Cells

UCLA researchers have identified a class of small molecule phosphodiesterase inhibitors that suppress let-7 target genes and inhibit cell growth in acute myeloid leukemia cancer cell lines.

Antimicrobial, Stimuli-responsive Polysaccharide

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

Controlled 'One-Cell-One-Bead' Encapsulation in Droplets

Improving droplet encapsulation of a single-cell and single-bead to increase pharmacological assay throughput.

Immunotherapy Against Aß-Mediated Inhibition of ADAM10 Activity

UCLA researchers in the Department of Neurology have developed a novel immunotherapy targeting a previously unexplored pathway of Aβ toxicity in Alzheimer’s disease.

Epigenetic Target for HIV and Latent Virus Eradication

Researchers at the University of California, Davis, have identified a target for therapeutic intervention and agents that disrupt HIV latency in patients under suppressive HIV therapy. It amplifies the effects of other latency reversal agents and primes the cells harboring the virus for immune clearance and death.

Preganancy Hormone-Containing Combination Products for the Continuous Treatment of Autoimmune Diseases

UCLA researchers in the Departments of Neurology have discovered that the combination of certain pregnancy hormones can treat autoimmune disorders like multiple sclerosis.

Chemically Modified Nell-1 and Methods of Making and Using the Same

UCLA researchers have developed ways to chemically modify NELL-1, an osteoinductive factor, that significantly prolong the in vivo circulation time of the protein and retain its osteoblastic activity without any appreciable cytotoxicity.

Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.

Small Molecules for Melanoma Treatment

Traditional anti-cancer treatments used for metastatic melanoma (skin cancer) can result in cell toxicity, poor efficacy, and low patient survival. UCI researchers have uncovered a class of potent compounds that inhibit cancer cell growth and induce cancer cell death by targeting RhoJ signaling pathways.

Anti-Oxidant Response Modifiers as Treatment for HIV-Associated Neurocognitive Disorder

UCLA researchers have identified anti-oxidative response modulators as a potential treatment for HIV-associated neurocognitive disorders (HAND).

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

  • Go to Page: